[Multicenter study of cefoperazone in Austria].
109 patients entered a multicentre study for treatment with Cefoperazone of respiratory, urogenital, and hepato-biliary tract infections, as well as peritonitis. The purpose of the study was to determine the efficacy, tolerance as well as the therapeutic advantages of a new agent of the group of betalactam-antibiotics which is excreted by the liver with the bile and--to a far lesser extent--by the kidneys. The mean duration of therapy was 7.2 days. The mean dosage was 2 g twice a day. Efficacy and tolerance of Cefoperazone were excellent.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001317:Austria; D001424:Bacterial Infections / Q000188:drug therapy; D001660:Biliary Tract Diseases / Q000188:drug therapy; D002438:Cefoperazone / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010538:Peritonitis / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy; D012874:Skin Diseases, Infectious / Q000188:drug therapy; D013530:Surgical Wound Infection / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D002438:Cefoperazone
Multicenterstudie mit Cefoperazon in Osterreich.